Efficacy, Safety And Tolerability Of Tofacitinib For Treatment Of Polyarticular Course Juvenile Idiopathic Arthritis (Jia) In Children And Adolescent Subjects
Phase of Trial: Phase III
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Tofacitinib (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 24 Jun 2016 Planned End Date changed from 1 Mar 2019 to 1 Apr 2019.
- 24 Jun 2016 Planned primary completion date changed from 1 Mar 2019 to 1 Apr 2019.